�
�
�
� � |
Parkinson's Disease News covers
all significant new research, reports, books, and resources concerning
Parkinson's Disease.
Articles are chosen on the basis
of their medical significance or potential interest. Our overwhelming priority
is the facts, regardless of whether they contradict prevailing views or vested
interests. Analysis and further information are provided
either to explain the background or implications, or to
balance misleading claims. If you notice errors or inadequacies, or dispute what is
written, or want to propose articles, please
e-mail
[email protected].
��� �
�����
�� ��
����
��� �
����
����
����

�
20th October 2014 - New research
CLINICAL
TRIAL RESULTS OF DUAL LAYER L-DOPA
�CLICK HERE
FOR A
PRINTABLE OR WHITE BACKGROUND VERSION OF THIS ARTICLE |
Dual layer L-dopa (IPX066), which is being developed for the treatment of
Parkinson's Disease, unusually and advantageously combines the immediate
release version of L-dopa with the controlled release version of L-dopa. An
application by Impax is with the FDA for the marketing of IPX066 as Rytary.
For more information go to
Rytary� ��������������������������������������������������������������������������������������������������������������������������������������������������������������������������������
The effect of Dual Layer L-dopa on Parkinson's Disease was compared to the
effect of Sinemet plus Entacapone, which is one of the most effective
formats of L-dopa. IPX066 demonstrated improved efficacy. The average dosage
of L-dopa used in IPX066, after accounting for availability, was 22% higher
than in Sinemet and Entacapone.
IPX066 demonstrated less "off" time
(3.8 hours instead of 5.2 hours per day). IPX066 demonstrated higher "on"
time without dyskinesia (11.4 hours instead of 10 hours per day). Other
measures favoured IPX066. There were more adverse events when taking IPX066.
The most common adverse events were dyskinesia, insomnia, and confusional
state for IPX066, and falling for Sinemet and Entacapone.
Reference :
Parkinsonism Related Disorders [2014] Aug 15 [Epub ahead of print]
(F.Stocchi, A.Hsu, S.Khanna, A.Ellenbogen, A.Mahler, G.Liang, U.Dillmann,
R.Rubens, S.Kell, S. Gupta)
Complete abstract�
For more news go to
Parkinson's Disease News
E-MAIL NOTIFICATION : If you would like to be
notified by e-mail when any new articles are added to Parkinson's Disease News,� please merely
e-mail
[email protected] with the message
"subscribe".� No form of identity is required.� E-mail addresses are
not used for any other purpose.

|
� �
�
�
�
�
�
�
�
�
�
�
�
�
� |